Who is sponsoring NCT07098988?

NCT07098988 is sponsored by CatalYm GmbH.

What drugs are being tested in NCT07098988?

Interventions in NCT07098988: Visugromab, Matching placebo for visugromab, Pembrolizumab 200 mg Q3W, Pemetrexed 500 mg/m^2, Carboplatin AUC 5.

Is NCT07098988 still recruiting?

NCT07098988 is currently recruiting now. Last updated 27 February 2026.

Last reviewed 2026-02-27 · How we verify

NCT07098988

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC

Recruiting now Phase 2 Last updated 27 February 2026

What this trial tests

Phase 2 trial testing Visugromab in Metastatic Non-Squamous Non-Small Cell Lung Cancer in 107 participants. Currently enrolling.

Timeline

1 August 2025

Primary endpoint
31 March 2029

31 March 2031

Quick facts

Lead sponsor	CatalYm GmbH
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	107
Start date	1 August 2025
Primary completion	31 March 2029
Estimated completion	31 March 2031
Sites	25 locations across Italy, Germany, Romania, Switzerland, United States, Spain

Drugs / interventions tested

Visugromab — full drug profile →
Matching placebo for visugromab — full drug profile →
Pembrolizumab 200 mg Q3W — full drug profile →
Pemetrexed 500 mg/m^2 — full drug profile →
Carboplatin AUC 5 — full drug profile →

Conditions studied

Metastatic Non-Squamous Non-Small Cell Lung Cancer — all drugs for Metastatic Non-Squamous Non-Small Cell Lung Cancer →
Adult Solid Tumor — all drugs for Adult Solid Tumor →

Sponsor

CatalYm GmbH — full company profile →

Who can join

18 and older, any sex, with Metastatic Non-Squamous Non-Small Cell Lung Cancer or Adult Solid Tumor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an exploratory, signal finding, randomized, placebo-controlled, blinded, multi-center Phase 2b trial of the anti GDF-15 antibody Visugromab (CTL-002) versus Placebo, combined with Immunochemotherapy (ICT: Pembrolizumab, Pemetrexed, Carboplatin) in the first-line treatment of participants with newly diagnosed metastatic non-squamous NSCLC. The trial consists of 3 Parts, a non-randomized Safety-run-in part (Part A) and the subsequent randomized Ph2b trial with 2 treatment arms. After the treatment of 15 participants with visugromab at the expansion dose, an interim safety and preliminary efficacy analysis will be conducted (Part B), followed by the treatment of the remaining participants (Part C).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Metastatic Non-Squamous Non-Small Cell Lung Cancer

Currently open trials in the same condition.

NCT07246863 — Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic N · Phase 2 · recruiting

Other CatalYm GmbH trials

Trials by the same sponsor.

NCT07246863 — Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic N · Phase 2 · recruiting
NCT06059547 — Neoadjuvant Immunotherapy Combined With the Anti-GDF-15 Antibody Visugromab to Treat Muscle Invasive Bladder Cancer · Phase 2 · active not recruiting
NCT04725474 — First-in-Human Study of the GDF-15 Neutralizing Antibody Visugromab (CTL-002) in Patients With Advanced Cancer (GDFATHER · Phase 1, PHASE2 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07098988 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by CatalYm GmbH
Last refreshed: 27 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07098988.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing